Senators question Allergan CEO on tribe patent deal

A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis.

Inventors Digest - August 2018 by Inventors Digest - Issuu

Tangible IP's Latest IP Market Update

Allergan CEO Defends Mohawk Tribe Restasis Patent Deal

Allergan does patent deal for Restasis with Native American tribe

Patent IPRs and Allergan's Sovereign Immunity Defense

A handful of Allergan's top shareholders want to bring back the old CEO as chairman

With new bill, Sen. McCaskill looks to end 'brazen' tribal licensing strategy Allergan started

Allergan deal with Mohawk tribe casts patent shadow

Pharma Giant Allergan Fears Embrace Of Sanders's Medicare For All Plan

Allergan's Mohawk Tribe Patent Defense Is Eyewash - Court